Both AstraZeneca and Ionis’ stocks took a hit at market open on 9 July after the companies announced that a Phase III trial of Wainua (eplontersen) in transthyretin-mediated amy ...

If approved, Keenova's Xiaflex would become the first FDA-approved therapy to reach patients with plantar fibromatosis.

More positive Phase II data from a subgroup further supports the trial expansion, which will lead further development.

Teva plans to start a Phase IIb study on TEV-‘408 in vitiligo during the final quarter of 2026 following positive results of a Phase Ib trial.

Kailera Therapeutics’ bet on Hengui Pharma’s oral glucagon-like peptide 1 receptor agonist (GLP-1RA) appears to be paying off following two late-stage wins in obesity and type ...

Brii Bio has reported topline EOT data from its ongoing Phase IIb ENRICH and ENHANCE trials assessing sequential and concurrent use of BRII-179, elebsiran, and PEG-IFNα to treat chronic HBV infection.

Genentech's divarasib posts this win as KRAS-targeting therapies demonstrate ‘game-changing’ potential in hard-to-treat cancers.

Curis has opened enrolment at 11 clinical sites for its Phase II TakeAim CLL trial, assessing the oral small molecule inhibitor emavusertib along with zanubrutinib for patients with CLL.

NeuroSense now has FDA clearance to take PrimeC to Phase III in ALS, as competition in the indication intensifies.

The retraction further weakens Amgen’s case for Tavneos’ continued use on the market as the drug comes under intense regulatory scrutiny.

Natera and Aveta Biomics have entered into a strategic partnership to support the latter’s AVTA 30-01, a global Phase III head and neck cancer trial assessing APG-157 in patients with LA-HNSCC.

Allucent has introduced the IGNITE aimed at improving speed, quality as well as predictability across clinical trial delivery.